Anthropic raises concern over of ‘existential risks to humanity’ from AI; AstraZeneca makes $2bn cancer drug tie-up – business live

The Guardian — Business has covered a development concerning “Anthropic raises concern over of ‘existential risks to humanity’ from AI; AstraZeneca makes $2bn cancer drug tie-up – business live,” with the available account limited to the facts included in the supplied text.

Rolling coverage of the latest economic and financial news The Financial Times have also scrutinised Anthropic’s IPO prospectus, and report that the Claude maker also provided investors with a clearer picture of the challenging economics of building state of the art AI models. The report also notes that The FT states : Anthropic stated it intends to spend $518bn on cloud, computing and infrastructure obligations in the coming years to support its rapid growth. The AI lab’s backers are confident Anthropic can list at a valuation of over $2tn, more than double the level achieved in its last funding round in May and beyond the $1.78tn achieved by Elon Musk’s SpaceX in June. They point to its extraordinary growth rate to justify their bullishness. “A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumour types with combinations alongside next-generation immunotherapies. Bispecifics targeting PD-1 and VEGF are rapidly advancing in development and have the potential to improve on current immunotherapies, particularly in lung, breast and gastrointestinal cancers. This opportunity to combine ivonescimab with AstraZeneca’s ADC portfolio, including with Sone-Ve, could enable new regimens that raise the bar for patients with cancer across the treatment landscape.”

Any statements, estimates or characterisations remain attributed to the people or organisations identified by the source. The excerpt alone does not provide a complete documentary record or necessarily include responses from every party involved.

Official statements or subsequent reporting may add context as the story develops. For now, this account is confined to information directly supported by the provided headline and excerpt.